Photodynamic therapy and imaging based on tumor-targeted nanoprobe, polymer-conjugated zinc protoporphyrin

Future Science OA

Volumn 1, Issue 3, 2015, Pages

  Fang, Jun ^a   Liao, Long ^a   Yin, Hongzhuan ^a,b   Nakamura, Hideaki ^a   Subr, Vladimir ^c   Ulbrich, Karel ^c   Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

fluorescent nanoprobe; photodynamic therapy; theranostic nanomedicine; tumor imaging; zinc protoporphyrin

Indexed keywords

AZOXYMETHANE; DEXTRAN SULFATE; DIMETHYLBENZ[A]ANTHRACENE; PHOTOSENSITIZING AGENT; PROTOPORPHYRIN ZINC; XENON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; COLON CANCER; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; FEMALE; FLUORESCENCE IMAGING; IRRADIATION; MALE; MALIGNANT NEOPLASM; NANOPROBE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RAT; SARCOMA CELL LINE; TUMOR GROWTH; TUMOR VOLUME;

EID: 84977865921     PISSN: None     EISSN: 20565623     Source Type: Journal    
DOI: 10.4155/fso.15.2     Document Type: Article

References (46)

1. McBride G. Studies expand potential uses of photodynamic therapy. J. Natl Cancer Inst. 94(23), 1740-1742 (2002).
2. Wilson BC. Photodynamic therapy for cancer: principles. Can. J. Gastroenterol. 16(6), 393-396 (2002).
3. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat. Rev. Cancer 3(5), 380-387 (2003).
4. Nowis D, Legat M, Grzela T et al. Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 25(24), 3365-3374 (2006).
5. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev. 61(4), 290-302 (2009).
6. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63(3), 136-151 (2011).
7. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387-6392 (1986).
8. Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv. Drug Deliv. Rev. 65(1), 60-70 (2013).
9. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63(3), 131-135 (2011).
10. Liu J, Ohta S, Sonoda A et al. Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy. J. Control. Release 117(1), 104-110 (2007).
11. Sibani SA, McCarron PA, Woolfson AD, Donnelly RF. Photosensitiser delivery for photodynamic therapy. Part 2: systemic carrier platforms. Expert Opin. Drug Deliv. 5(11), 1241-1254 (2008).
12. Oh IH, Min HS, Li L et al. Cancer cell-specific photoactivity of pheophorbide a-glycol chitosan nanoparticles for photodynamic therapy in tumor-bearing mice. Biomaterials 34(27), 6454-6463 (2013).
13. Shiah JG, Sun Y, Peterson CM, Straight RC, Kopecek J. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments. Clin. Cancer Res. 6(3), 1008-1015 (2000).
14. Regehly M, Greish K, Rancan F, Maeda H, Böhm F, Röder B. Water-soluble polymer conjugates of ZnPP for photodynamic tumor therapy. Bioconjug. Chem. 18(2), 494-499 (2007).
15. Iyer AK, Greish K, Seki T et al. Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J. Drug Target. 15(7-8), 496-506 (2007).
16. Nakamura H, Liao L, Hitaka Y et al. Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo. J. Control. Release 165(3), 191-198 (2013).
17. Jin CS, Cui L, Wang F, Chen J, Zheng G. Targeting-triggered porphysome nanostructure disruption for activatable photodynamic therapy. Adv. Healthc. Mater. 3(8), 1240-1249 (2014).
18. Gabriel D, Zuluaga MF, Lange N. On the cutting edge: protease-sensitive prodrugs for the delivery of photoactive compounds. Photochem. Photobiol. Sci. 10(5), 689-703 (2011).
19. Fang J, Akaike T, Maeda H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis 9(1), 27-35 (2004).
20. Sahoo SK, Sawa T, Fang J et al. Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug. Chem. 13(5), 1031-1038 (2002).
21. Fang J, Sawa T, Akaike T et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 63(13), 3567-3574 (2003).
22. Iyer AK, Greish K, Fang J, Murakami R, Maeda H. High-loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor. Biomaterials 28(10), 1871-1881 (2007).
23. Fang J, Greish K, Qin H et al. HSP32 (HO-1) inhibitor, copoly(styrene-maleic acid)-zinc protoporphyrin IX, a water-soluble micelle as anticancer agent: in vitro and in vivo anticancer effect. Eur. J. Pharm. Biopharm. 81(3), 540-547 (2012).
24. Editorial. Welcome clinical leadership at NICE. Lancet 372(9639), 601 (2008).
25. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563-572 (2009).
26. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 101(15), 1044-1048 (2009).
27. Taieb J, Tabernero J, Mini E et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 15(8), 862-873 (2014).
28. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007).
29. Sjöblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 314(5797), 268-274 (2006).
30. Vicent MJ, Ringsdorf H, Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv. Drug Deliv. Rev. 61(13), 1117-1120 (2009).
31. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2(5), 347-360 (2003).
32. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 100(4), 572-579 (2009).
33. Dougherty TJ, Gomer CJ, Henderson BW et al. Photodynamic therapy. J. Natl Cancer Inst. 90(12), 889-905 (1998).
34. Moan J, Iani V, Ma LW. Choice of the proper wavelength for photochemotherapy. In:Photochemotherapy Photodynamic Therapy and Other Modalities. Ehrenberg B, Jori G, Moan J (Eds). Proc SPIE, Bellingham, Washington, DC, USA, 2625, 544-549 (1996).
35. Rigual NR, Shafirstein G et al. Adjuvant intraoperative photodynamic therapy in head and neck cancer. JAMA Otolaryngol. Head Neck Surg. 139(7), 706-711 (2013).
36. Yano T, Muto M, Minashi K et al. Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. Int. J. Cancer 131(5), 1228-1234 (2012).
37. Kobayashi W, Liu Q, Nakagawa H et al. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse. Oral Oncol. 42(1), 46-50 (2006).
38. Pech O, Nagy CD, Gossner L, May A, Ell C. Photodynamic therapy of human Barrett's cancer using 5-aminolaevulinic acid-induced protoporphyrin IX: an in-vivo dosimetry study in athymic nude mice. Eur. J. Gastroenterol. Hepatol. 14(6), 657-662 (2002).
39. Seshadri M, Bellnier DA, Vaughan LA et al. Light delivery over extended time periods enhances the effectiveness of photodynamic therapy. Clin. Cancer Res. 14(9), 2796-2805 (2008).
40. Henderson BW, Busch TM, Vaughan LA et al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res. 60(3), 525-529 (2000).
41. Busch TM, Wileyto EP, Emanuele MJ et al. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. Cancer Res. 62(24), 7273-7279 (2002).
42. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br. J. Cancer 77(9), 1386-1394 (1998).
43. Duncan R, Sat-Klopsch YN, Burger AM, Bibby MC, Fiebig HH, Sausville EA. Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother. Pharmacol. 72(2), 417-427 (2013).
44. Tsukigawa K, Nakamura H, Fang J et al. Effect of different chemical bonds in pegylation of zinc protoporphyrin that affects drug release, intracellular uptake, and therapeutic effect in the tumor. . Eur J Pharm Biopharm.. 89, 259-270 (2015).
45. Nakamura H, Etrych T, Chytil P et al. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl) methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J. Control. Release 174, 81-87 (2014).
46. Malugin A, Kopecková P, Kopecek J. Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. J. Control. Release 124(1-2), 6-10 (2007).